Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases-Reference-Cited by-同舟云学术

Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases

Published:2021-08-09 Issue:8 Volume:4 Page:e2118416
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Wang Chongkai¹,Sandhu Jaideep¹,Ouyang Ching²³,Ye Jian⁴,Lee Peter P.⁴,Fakih Marwan¹

Affiliation:

1. Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California

2. Center for Informatics, City of Hope National Medical Center, Duarte, California

3. Department of Computational and Quantitative Medicine, Beckman Research Institute of the City of Hope, Duarte, California

4. Department of Immuno-oncology, Beckman Research Institute of the City of Hope, Duarte, California

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2782836/wang_2021_oi_210539_1627686286.15836.pdf

Reference39 articles.

1. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.;Llosa;Cancer Discov,2015

2. PD-1 blockade in tumors with mismatch-repair deficiency.;Le;N Engl J Med,2015

3. Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.;O’Neil;PLoS One,2017

4. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.;Eng;Lancet Oncol,2019

5. 533PD-BACCI: a phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): an ACCRU network study.;Mettu;Annals of Oncology,2019

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for gastric cancer and liver metastasis: Is it time to bid farewell;World Journal of Gastrointestinal Surgery;2024-08-27

2. Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?;Current Oncology Reports;2024-07-30

3. Impact of immunotherapy on liver metastasis;World Journal of Gastrointestinal Surgery;2024-07-27

4. STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer;Future Oncology;2024-07-23

5. Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms;Frontiers in Immunology;2024-07-19